- Home
- BEAT vs MIRA Comparison
BEAT vs MIRA Comparison
Compare BEAT & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BEAT | MIRA |
|---|---|---|
| Founded | 2015 | 2020 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 31.3M |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | BEAT | MIRA |
|---|---|---|
| Price | $0.43 | $0.71 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $3.50 | N/A |
| AVG Volume (30 Days) | ★ 16.5M | 161.8K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.07 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,197.12 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $0.60 |
| 52 Week High | $4.00 | $2.45 |
Technical Indicators
Market Signals| Indicator | BEAT | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 46.56 | 39.59 |
| Support Level | $0.37 | $0.61 |
| Resistance Level | $0.52 | $0.82 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 11.41 | 21.50 |
Price Performance
Historical ComparisonAbout BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.